Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a Chinese bioengineering company, has announced that its subsidiary, Technogenetics S.P.A. (TGS), is poised to acquire an additional 20% stake in TGS. The stake is currently held by Altergon Italia S.r.l., and the transaction is valued at EUR 15.34 million (USD 16.4 million). Kehua Bio already possesses an 80% stake in TGS, and this acquisition will result in Kehua Bio owning 100% of TGS upon the closure of the transaction.- Flcube.com
Recent news:
-
Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation -
Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation -
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline -
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies -
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
